Latest:
Dr. Howard Sharp on the Importance of Racial and Ethnic Diversity in Pediatric Clinical Trials
Katianne M. Howard Sharp, PhD, discusses the importance of racial and ethnic diversity in clinical trials for pediatric patients with cancer.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Richard T. Lee, MD
Richard T. Lee, MD is the Cherng Family Director’s Chair of the Center for Integrative Oncology, as well as medical director and clinical professor of Supportive & Integrative Medicine in the Department of Supportive Care Medicine at City of Hope.
Latest:
Dr Lee on the Role of Integrative Medicine in Oncology Care
Richard Lee, MD, FASCO, discusses the role of integrative medicine in oncology care.
Kanwarpal S. Kahlon, MD
Kanwarpal S. Kahlon, MD, is an associate clinical professor of medicine at the UCLA School of Medicine.
Latest:
Dr Kahlon on the Availability of Generic Eltrombopag for Anemia & Thrombocytopenia
Kanwarpal S. Kahlon, MD, discusses the benefits of the availability of generic eltrombopag formulations for aplastic anemia and immune thrombocytopenia.
Justin T. Jordan, MD, MPH, FAAN
Justin T. Jordan, MD, MPH, FAAN, is an associate professor of neurology, head of the Neuro-Oncology Section, and an associate professor of O'Donnell Brain Institute at UT Southwestern Medical Center.
Latest:
Dr Jordan on Challenges With Drug Development in Adult NF1-Associated PN
Justin T. Jordan, MD, MPH, FAAN, discusses treatment challenges and recent progress made with targeted therapies in adult NF1-associated PNs.
Talha Munir, MBChB, PhD
Tahla Munir, MBChB, PhD, is a consultant hematologist at Leeds Teaching Hospitals NHS Trust and deputy chair of the United Kingdom National Cancer Research Institute Chronic Lymphocytic Leukemia Study Group, in Leeds, UK.
Latest:
Dr Munir on a MAIC of Zanubrutinib vs Fixed-Duration Acalabrutinib Plus Venetoclax in CLL
Tahla Munir, MBChB, PhD, discusses the rationale for a MAIC of the phase 3 SEQUOIA and AMPLIFY trials in chronic lymphocytic leukemia.
Charu Aggarwal, MD, MPH
Charu Aggarwal, MD, MPH, is a physician leader in Airways Malignancies Research, director of Precision Oncology Innovation at Penn Center for Cancer Care Innovation, section chief of Head & Neck and Thoracic Cancers, Hematology-Oncology, and the Leslye M. Heisler Professor for Lung Cancer Excellence at Penn Medicine in Philadelphia, Pennsylvania.
Latest:
Final Reflections: Key Takeaways and Future Opportunities With QCS and TROP2 NMR
Panelists discuss the introduction of quantitative cell scoring (QCS) for TROP2 as a significant artificial intelligence (AI)-driven advancement in oncology, emphasizing its ability to provide precise, quantitative biomarker assessment that complements molecular data like EGFR status. The panelists also highlight the importance of pathologists embracing digital pathology tools to enhance diagnostic accuracy and treatment planning while recognizing the technology’s early but promising role in expanding patient identification for targeted therapies and its potential broader impact on precision oncology.